Armenta

Company Overview

Snapshot

Founded in June 2018, Armenta operates with 11–50 employees and has raised $8.35M across three funding rounds from three investors. The company is focused on developing novel therapies for dairy cattle diseases.

Business overview

Armenta is an agriculture technology company that develops proprietary acoustic pulse therapy (APT) technology and related devices for the non-antibiotic treatment of mastitis in dairy cows. The company's core technology aims to prevent monetary losses resulting from pathologies in dairy cattle, serving the livestock and dairy sectors within the broader Agriculture & Food Technologies and Health Tech & Life Sciences industries.

Company Intelligence Q&A

What is Armenta's primary focus?

Armenta is primarily focused on developing novel, non-antibiotic treatments for mastitis in dairy cows, utilizing proprietary acoustic pulse therapy (APT) technology.

When was Armenta founded?

Armenta was founded in June 2018.

What is Armenta's total disclosed funding?

Armenta has raised a total of $8.35M across three funding rounds. Key investors include Together We Invest and Dragones Venture Partners.